Loading
Mezigdomide is the most potent oral cereblon modulator, producing responses in about 40% of triple-class-refractory myeloma with dexamethasone alone.
Mezigdomide is the most potent oral cereblon E3 ligase modulator (CELMoD) in development, producing rapid and deep degradation of Ikaros and Aiolos with strong T-cell co-stimulation. In CC-92480-MM-001, mezigdomide with dexamethasone alone produced an ORR of 41% in heavily pretreated, triple-class-refractory myeloma, including responses in 30% of patients with extramedullary disease, a group that responds poorly to most therapies. Two phase 3 trials are ongoing: SUCCESSOR-1 compares Mezi-Vd with Pom-Vd, and SUCCESSOR-2 compares Mezi-Kd with Kd. The open questions are durability of response and whether cytopenias and infections limit its use in combination. BMS develops it alongside the related CELMoD iberdomide. It is a pill that acts on the same target as lenalidomide but strongly enough to work when that drug and its successors have failed.
High-affinity cereblon modulator; rapid, deep Ikaros/Aiolos degradation with strong T-cell co-stimulation.
1.Mezigdomide binds its target with one end and an E3 ubiquitin ligase with the other.
Compare all products across the US, EU, UK, Japan, China and Australia →
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Mezigdomide" OR ABSTRACT:"Mezigdomide" OR TITLE:"CC-92480" OR ABSTRACT:"CC-92480") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mezigdomide, not a curated reading list.
Shares A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe, Cereblon E3 ligase modulators (CELMoDs), Ubiquitin-proteasome system & protein homeostasis, Relapsed or refractory multiple myeloma.
Shares Cereblon E3 ligase modulators (CELMoDs), Relapsed or refractory multiple myeloma, PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb.
Shares Cereblon E3 ligase modulators (CELMoDs), PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb, Multiple myeloma.
Shares A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe, A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W, A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre, Ubiquitin-proteasome system & protein homeostasis.
Shares Cereblon E3 ligase modulators (CELMoDs), PROTACs & molecular glues (targeted protein degradation), Bristol Myers Squibb, Multiple myeloma.
Shares Cereblon E3 ligase modulators (CELMoDs), Ubiquitin-proteasome system & protein homeostasis, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Bristol Myers Squibb, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Bristol Myers Squibb, Multiple myeloma.